WCK-4234 sodium

• CAT Number: I038264
• CAS Number: 1804915-68-1
• Molecular Formula: C7H8N3NaO5S
• Molecular Weight: 269.21
• Purity: 98%
• Synonyms: WCK-4234; WCK 4234; WCK4234.
• Target: Beta-lactamase
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: -20°C, away from moisture
• IUPAC Name: sodium;[(2S,5R)-2-cyano-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] sulfate
• InChI: InChI=1S/C7H9N3O5S.Na/c8-3-5-1-2-6-4-9(5)7(11)10(6)15-16(12,13)14;/h5-6H,1-2,4H2,(H,12,13,14);/q;+1/p-1/t5-,6+;/m0./s1
• InChIKey: RYJWKSOILDDAHI-RIHPBJNCSA-M
• SMILES: C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)[O-])C#N.[Na+]

WCK-4234 sodium（Cat No.:I038264）is a novel antibacterial agent designed to target multi-drug-resistant bacterial infections, especially those caused by gram-negative pathogens. It functions by inhibiting key bacterial enzymes, disrupting cell wall synthesis and leading to cell death. WCK-4234 sodium shows promise against pathogens resistant to traditional antibiotics, including carbapenem-resistant strains, making it a potential option for combating hospital-acquired infections. Its potent efficacy and broad-spectrum activity are being studied in clinical trials to assess safety and effectiveness, positioning WCK-4234 sodium as a valuable candidate in the fight against antibiotic resistance.

Reference

1: Papp-Wallace KM, Nguyen NQ, Jacobs MR, Bethel CR, Barnes MD, Kumar V,
Bajaksouzian S, Rudin SD, Rather PN, Bhavsar S, Ravikumar T, Deshpande PK, Patil
V, Yeole R, Bhagwat SS, Patel MV, van den Akker F, Bonomo RA. Strategic
approaches to overcome resistance against Gram negative pathogens using
β-lactamase inhibitors and β-lactam enhancers: The activity of three novel
diazabicyclooctanes, WCK 5153, zidebactam (WCK 5107), and WCK 4234. J Med Chem.
2018 Apr 7. doi: 10.1021/acs.jmedchem.8b00091. [Epub ahead of print] PubMed PMID:
29627985.
2: Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Papp-Wallace KM, Bonomo RA,
Oliver A. Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against
Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.
Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01238-17. doi:
10.1128/AAC.01238-17. Print 2017 Nov. PubMed PMID: 28848013; PubMed Central
PMCID: PMC5655067.
3: Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Papp-Wallace KM, Bonomo RA,
Oliver A. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing
Potent “β-Lactam Enhancer” Activity against Pseudomonas aeruginosa, Including
Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones. Antimicrob
Agents Chemother. 2017 May 24;61(6). pii: e02529-16. doi: 10.1128/AAC.02529-16.
Print 2017 Jun. PubMed PMID: 28289035; PubMed Central PMCID: PMC5444176.